DelveInsight's "Duchenne Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...

Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...

Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Design Therapeutics. ;'> Currently, the analyst consensus on Pyxis Oncology is ...

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and ...

That professional was Guggenheim's Debjit Chattopadhyay, who initiated his Edgewise Therapeutics coverage with a buy recommendation, and price target of $41 per share. That's well more than double ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) was downgraded by research analysts at Scotiabank from a “sector outperform” rating to a “sector perform” rating in a research ...

The last time I wrote about Edgewise Therapeutics, Inc. (NASDAQ:EWTX) it was in a Seeking Alpha article entitled "Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data." In the ...

Hinterhaus Productions via Getty Images Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical trial. The drug accomplished its main goal ...

Edgewise Therapeutics shares are trading lower by 23.3% during Wednesday's session. The company announced an approximate $200 million offering. Beat the market with ready-to-go trades and pro ...